Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02157662Completed

GISSI Outliers CAPIRE

Role: lead

NCT02283970Completed

Investigation of Patients With BAV Requiring Valve and/or Aortic Repair (GISSI Outliers VAR)

Role: lead

NCT00336336Phase 3Completed

GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF

Role: lead

NCT00376272Phase 3Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Role: lead

All 4 trials loaded